Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions [Yahoo! Finance]
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St